A TLR4 agonist liposome formulation effectively stimulates innate immunity and enhances protection from bacterial infection
Innate Immunity · 2023-04 · 29 (3-4) · 45-57
DOI: 10.1177/17534259231168725 ↗Kurz gefasst
Fachartikel in der Zeitschrift Innate Immunity, online erschienen am 21.04.2023. Verfasst von Jodi F Hedges und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Cell Biology, Montana State University, P.O. Box 173610, Bozeman, MT, USA. Hauptthemen laut MEDLINE: Brucella abortus, Brucellosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, National Institute of Food and Agriculture, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Stimulation of innate immunity can protect against infectious insult and could be used in combination with other therapies. Since antibiotic resistance is an increasing concern, strategies to reduce the dose or eliminate the need for these drugs are warranted. Lipo-CRX is a formulation in which the TLR4 agonist CRX-527 is incorporated into lipid membranes in liposomes. Lipo-CRX is less inflammatory than either CRX-527 or LPS, but retains unique capacity to enhance host defense responses. We compared lipo-CRX to other agonists in vitro using mammalian cells and in vivo in mice, and assessed indicators of innate immune responses and protection from bacterial infection. Lipo-CRX is similar to E. coli LPS in its capacity to activate bovine γδ T cells and to recruit neutrophils into mouse lungs, but with less reactivity in the LAL assay. However, lipo-CRX uniquely induced the production of systemic innate immune cytokines. In the mouse model of brucellosis, delivery of lipo-CRX to the lungs reduced the dissemination of B. abortus. While lipo-CRX or the antibiotic ampicillin alone did not alter B. abortus burdens in the lung, the combination had a synergistic beneficial effect. Our data suggest that stimulating the innate immune system with lipo-CRX, either alone or when combined with antibiotics, can enhance bacterial clearance in the mouse model of brucellosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Cell Biology, Montana State University, P.O. Box 173610, Bozeman, MT, USA.
- Totem BioSciences, 240 Old Corvallis Road, Hamilton, MT 59840, USA.
ORCID-Profile: Jodi F Hedges
Förderung
- NIAID NIH HHS
- National Institute of Food and Agriculture
- National Institute of Allergy and Infectious Diseases
- Montana Agricultural Experiment Station
Zitieren
APA
Hedges, J. F., Snyder, D. T., Robison, A., Thompson, M. A., Aspelin, K., Plewa, J., Baldridge, J., & Jutila, M. A. (2023). A TLR4 agonist liposome formulation effectively stimulates innate immunity and enhances protection from bacterial infection. Innate Immunity, 29(3-4), 45-57. https://doi.org/10.1177/17534259231168725
Vancouver
Hedges JF, Snyder DT, Robison A, Thompson MA, Aspelin K, Plewa J, et al. A TLR4 agonist liposome formulation effectively stimulates innate immunity and enhances protection from bacterial infection. Innate Immunity. 2023;29(3-4):45-57. doi:10.1177/17534259231168725
BibTeX
@article{Hedges2023,
author = {Hedges, Jodi F and Snyder, Deann T and Robison, Amanda and Thompson, Macy A and Aspelin, Klara and Plewa, Jack and Baldridge, Jory and Jutila, Mark A},
title = {A TLR4 agonist liposome formulation effectively stimulates innate immunity and enhances protection from bacterial infection},
journal = {Innate Immunity},
year = {2023},
volume = {29},
number = {3-4},
pages = {45--57},
doi = {10.1177/17534259231168725}
}
EUVIMED